Dasatinib

Broad-spectrum tyrosine kinase inhibitor

Dasatinib is a potent, orally active small-molecule inhibitor of multiple tyrosine kinases, including Bcr-Abl, Src family kinases, c-Kit, PDGFR, and EphA2. It inhibits Src, Abl, Lck, and c-Kit with an IC₅₀ of 0.8 nM, 1 nM, 0.4 nM, and 79 nm, respectively. Originally developed as a second-generation treatment for chronic myeloid leukemia (CML), it is widely used in cancer research and cell signaling studies due to its broad kinase inhibition profile.

Key features and applications include:

- **Multi-Targeted Inhibition:** Blocks both receptor and non-receptor tyrosine kinases, including drug-resistant Bcr-Abl mutants.
- Cancer Research: Used to study leukemia, solid tumors, and kinase-driven malignancies.
- Cell Signaling Studies: Investigates pathways involving Src, Abl, and PDGFR signaling.
- **Immunology:** Modulates T-cell activation and natural killer (NK) cell function.
- **Fibrosis Models:** Explored for its anti-fibrotic effects in liver and lung disease models.
- Autophagy & Apoptosis: Induces programmed cell death and autophagy in various cancer cell lines.

Relevant disease states include:

- Chronic Myeloid Leukemia (CML): FDA-approved for treatment of CML, especially in cases resistant to imatinib.
- Acute Lymphoblastic Leukemia (ALL): Effective in Philadelphia chromosome-positive (Ph+) ALL.
- **Solid Tumors:** Investigated in breast, prostate, and pancreatic cancers for its anti-proliferative effects.
- **Fibrotic Diseases:** Studied for its potential to reduce fibrosis by targeting PDGFR and Src pathways.

• **Neurodegenerative Disorders:** Explored for neuroprotective effects via modulation of kinase signaling.


Ordering Information

Order Online »

ENZ-CHM333-0025 25mg

Manuals, SDS & CofA

View Online »



Handling & Storage

Use/Stability As indicated on product label or CoA when stored as recommended.

Short Term Storage -20°C

Long Term Storage -20°C

Shipping Ambient Temperature

Regulatory Status RUO - Research Use Only

Product Details

Alternative Name BMS-354825, N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-

hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-

5-thiazolecarboxamide

Appearance White or off-white solid.

CAS 302962-49-8

Couple Target Abl, c-Kit, p56lck tyrosine kinase, Src kinase

Couple Type Inhibitor

 $\mathbf{C_{22}H_{26}CIN_{7}O_{2}S}$

Identity Determined by NMR.

MW 488.01

Purity ≥98% (TLC)

Soluble in DMSO (200 mg/mL).

Last modified: July 28, 2025

